Compare HUN & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUN | COAG |
|---|---|---|
| Founded | 1970 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2004 | 2026 |
| Metric | HUN | COAG |
|---|---|---|
| Price | $9.33 | $40.94 |
| Analyst Decision | Hold | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $12.09 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 326.7K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | ★ 2.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,683,000,000.00 | N/A |
| Revenue This Year | $3.08 | N/A |
| Revenue Next Year | $5.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.30 | $27.47 |
| 52 Week High | $16.09 | $55.42 |
| Indicator | HUN | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 36.39 | 36.43 |
| Support Level | N/A | $29.54 |
| Resistance Level | $10.60 | $51.50 |
| Average True Range (ATR) | 0.32 | 3.17 |
| MACD | 0.04 | -0.93 |
| Stochastic Oscillator | 14.92 | 9.99 |
Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. The product portfolio of the company comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, and others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. The company derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.